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Background: Despite the recent identification of several prognostic gene signatures, the lack of common genes
among experimental cohorts has posed a considerable challenge in uncovering the molecular basis underlying
hepatocellular carcinoma (HCC) recurrence for application in clinical purposes. To overcome the limitations of
individual gene-based analysis, we applied a pathway-based approach for analysis of HCC recurrence.
Results: By implementing a permutation-based semi-supervised principal component analysis algorithm using the
optimal principal component, we selected sixty-four pathways associated with hepatitis B virus (HBV)-positive HCC
recurrence (p < 0.01), from our microarray dataset composed of 142 HBV-positive HCCs. In relation to the public
HBV- and public hepatitis C virus (HCV)-positive HCC datasets, we detected 46 (71.9%) and 18 (28.1%) common
recurrence-associated pathways, respectively. However, overlap of recurrence-associated genes between datasets
was rare, further supporting the utility of the pathway-based approach for recurrence analysis between different
HCC datasets. Non-supervised clustering of the 64 recurrence-associated pathways facilitated the classification of
HCC patients into high- and low-risk subgroups, based on risk of recurrence (p < 0.0001). The pathways identified
were additionally successfully applied to discriminate subgroups depending on recurrence risk within the public
HCC datasets. Through multivariate analysis, these recurrence-associated pathways were identified as an
independent prognostic factor (p < 0.0001) along with tumor number, tumor size and Edmondson’s grade.
Moreover, the pathway-based approach had a clinical advantage in terms of discriminating the high-risk
subgroup (N = 12) among patients (N = 26) with small HCC (<3 cm).
Conclusions: Using pathway-based analysis, we successfully identified the pathways involved in recurrence of
HBV-positive HCC that may be effectively used as prognostic markers.
Keywords: Recurrence-associated pathway, Hepatocellular carcinoma, Principal component analysis, Prognosis,
Risk, Small tumorBackground
Various gene signatures related to the survival and re-
currence of hepatocellular carcinoma (HCC) have been
identified using microarray analysis, and proposed to
supplement clinicopathological prognostic factors for
prediction of patient outcomes [1-4]. In fact, prognostic* Correspondence: kssuh@snu.ac.kr; khlee@kcch.re.kr
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based on gene expression, that can overcome the limita-
tions of clinical prognostic factors [5,6]. Interestingly,
prognostic genes can be extracted from not only HCC,
but also adjacent non-tumor liver tissues [7,8]. However,
the heterogeneous clinicopathological and biological nature
of HCCs makes it difficult to identify significant common
genes that fit to different datasets [7,9]. Therefore, elu-
cidation of the common biological functions related to
prognosis that may be applicable to different datasets is
also difficult.is is an Open Access article distributed under the terms of the Creative
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based approach is the use of functionally related prede-
fined gene sets, such as pathways, instead of individual
genes [10,11]. Pathway analysis provides biological infor-
mation that facilitates characterization of the functional
network and the relationships between selected signifi-
cant genes [12]. A number of methods have been pro-
posed to identify the pathways associated with prognosis
[10,13]. Recent reports also indicate that rather than
whole genes, a subset of genes correlated with sample
phenotype is more accurate in predicting clinical out-
comes of patients [14].
Among the diverse factors implicated in HCC devel-
opment, hepatitis B (HBV) and hepatitis C viruses
(HCV) are the major etiological risk factors. Although
HCCs infected chronically with HBV and HCV are not
distinguishable from histological and clinical evalua-
tions [15], studies to date consistently imply that differ-
ent molecular mechanisms underlie the development of
HBV- and HCV-positive HCCs [16,17]. We additionally
observed functional differences and similarities between
the development of HCV- and/or HBV-positive HCC at
the pathway level [12]. These results strongly suggest
differences in biological behavior and consequent re-
sponses to treatment between HBV and HCV-positive
HCCs.
In the present study, we implemented the pathway-
based supervised principal component analysis (PCA) with
random permutations to identify recurrence-associated
pathways of HBV-positive HCC. Comparison of our HBV-
positive recurrence-associated pathways with those from
two public datasets of HBV and HCV positive-HCCs
revealed significant overlap of pathways, despite limited
common genes between the datasets. The set of recurrence-
associated pathways identified in this study effectively
facilitated the stratification of HBV-positive HCC pa-
tients according to risk of recurrence. Our pathway-
based approach should therefore provide clinically
useful molecular insights into the mechanisms under-
lying HCC recurrence.
Results
To determine the biological pathways associated with
HCC prognosis, we established a genome-wide gene ex-
pression dataset via cDNA microarray of 142 HCC cases
positive for HBV. A schematic diagram of the overall
procedure for selection of pathways associated with re-
currence is presented in Figure 1.
Identification of genes related to HCC recurrence
Initially, using the microarray dataset and long-term
follow-up clinical data, we assessed the implications of
gene expression on HCC recurrence. In our cohort,
median overall and recurrence free-survival times were73.0 and 26.5 months, respectively. As an initial attempt,
we extracted a subset of 209 genes correlated with HCC
recurrence (log rank p-value < 0.01) (Additional file 1:
Table S1). When these recurrence-associated genes were
subjected to the unsupervised clustering method [7,14],
their hierarchical clustering led to the discrimination of
HCC patients into low-risk and high-risk subclasses
(Figure 2A). Kaplan-Meier plot of recurrence-free survival
based on expression of the 209 recurrence-associated
genes (Figure 2B) showed significant discrimination of
HCC patients according to risk, in which median
recurrence-free survival rates of low (N = 69) and high-
risk (N = 73) subgroups were 64.6 and 13.0 months
(log rank p-value <0.0001), respectively. Upon further
differentiation of these patients based on 2 years after
surgery, defined as a cut-off for early recurrence [18,19],
those showing recurrence within the 2-year period were
classified into the high-risk subgroup.
To further evaluate the expression profiles for recurrence-
free survival, we compared recurrence-associated genes
of our current dataset with those from two public HCC
datasets with available recurrence information, specific-
ally, a HBV-positive HCC dataset (GSE14520, termed
‘public HBV-HCC’) [3] and HCV-positive HCC dataset
(GSE17856) (‘public HCV-HCC’) [4]. In total, 503 and
43 genes from these two public datasets were selected,
respectively (log rank p-value < 0.01). Comparison of
the recurrence-related genes between datasets (209, 503
and 43 genes from our HBV-HCC, public HBV-HCC and
HCV-HCC datasets, respectively) disclosed a limited
number of common genes (Figure 2C). Only ten genes
overlapped between our HBV-HCC and public HBV-
HCC despite common viral etiology. Moreover, no
common genes were identified among the three data-
sets. Indeed, the lack of common genes among different
microarray datasets is the most significant problem in
analysis of prognosis of tumors, including HCC [9,20].
Comparison of clinical distribution in HCC datasets
The distributions of clinical variables in the three data-
sets, including ours, are presented in Additional file 2:
Table S2. Owing to the lack of specific variables, such as
tumor differentiation and fibrosis, in the public HBV-
HCC dataset, comparison of the datasets was difficult.
In addition, tumor stage (available from all three data-
sets) was different among datasets. Specifically, the
proportion of advanced-stage tumors III and IV in our
HBV-HCC dataset was 34.5%, compared to those of
public HBV-HCC (22.8%) and HCV-HCC datasets
(25.6%) (p-value < 0.0001). However, the incidence of re-
currence in our HBV-HCC dataset showed a biphasic
pattern (Figure 3A), similar to the public HBV-HCC
dataset [3]. Specifically, the cumulative recurrence rate
was 33.80% per year during the first two years after
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Figure 1 Schematic illustration of the analysis strategy. The initial dataset was randomly divided into training and test sets. In a training set,
genes below the threshold p-value in a pathway were subjected to PCA. Two models were constructed, specifically, one principal component
model using the most significantly associated principal component and weighted model using multiple principal components, and evaluated in
the test set. This procedure was repeated 1,000 times with random training and test sets. Finally, median values of statistics from test sets were
measured to select significant pathways.
Kim et al. BMC Genomics  (2015) 16:279 Page 3 of 15surgical resection of tumor in our HBC-HCC, whereas
the rate decreased to 4.01% per year beyond two years
after surgery (Figure 3A). In agreement with this result,
the recurrence rate per month peaked during the first
two years and persisted through the following years
(Figure 3B). In addition, tumor differentiation and
fibrosis stages were similar between our dataset and
public HCV-HCC, indicating clear advantages in com-
paring expression patterns and pathways associated
with recurrence.
Identification of recurrence-associated pathways between
different HCC datasets
To overcome the limitations of the gene-based ap-
proach, we applied a pathway-based semi-supervised
PCA approach. Following the overall analytical procedure
depicted in Figure 1, we initially determined a threshold
p-value that maximally generated significant pathways ineach dataset. Based on plots showing changes in the num-
ber of significant pathways when the p-value is gradually
increased, threshold p-value were determined as 0.11, 0.07
and 0.12, and among a total of 882 pathways, we subse-
quently obtained 64, 90 and 32 pathways of maximum
significance (log-rank p-value < 0.01 in the test set) for our
HBV-HCC, public HBV-HCC and public HCV-HCC data-
sets, respectively (Figure 4A-C). Among the 64 significant
pathways identified within our HBV-HCC dataset, 46
(71.9%) and 18 (28.1%) were in common with 90 and 32
significant pathways of public HBV-HCC and HCV-HCC
datasets, respectively (Figure 4D). In contrast to pathway-
based analysis showing significant overlap between the
datasets, the gene-based approach revealed a low rate
of overlap of significant genes (12.9% and 8.3%, re-
spectively) under conditions of the same threshold
p-values (Figure 4E). Moreover, the majority of signifi-
cant genes from each dataset were not commonly
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Figure 3 Recurrence rates in the HBV-HCC dataset. (A) Cumulative recurrence rate of HCC over time. (B) Recurrence rate of HCC per month
over time.
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Figure 2 Cluster analysis of recurrence-related genes. (A) Dendrogram of clustering pattern measured from the matrix of 209 recurrence-associated
genes (Cox regression p-value < 0.01) from our HBV-HCC. Samples were classified into two subgroups: low-risk and high-risk based on recurrence outcome.
The black bar indicates patients with early recurrence within 2 years after surgery. Columns represent individual samples, and rows genes. Red and green
colors reflect high and low expression levels, respectively, as indicated by scale bars. (B) Kaplan-Meier plots for recurrence rates of the low- and high-risk
subgroups. P-values were obtained using the log-rank test. (C) Overlap of recurrence-associated genes (Cox regression p-value < 0.01) among datasets.
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Figure 4 Determination of threshold p-value and comparison of recurrence-related features among the three HCC datasets. Starting with gene of
the lowest univariate Cox p-value, permutation-based pathway analysis was applied by gradually increasing the p-value. The maximum average
number of pathways below p-value of 0.01 in the test set was measured at threshold p-values of 0.11, 0.07 and 0.12 from (A) HBV-HCC, (B) public
HBV-HCC and (C) public HCV-HCC, respectively, as indicated with arrows. (D) Overlap of recurrence-associated pathways obtained at threshold
p-values among datasets. (E) Overlap of recurrence-associated genes at threshold p-values among datasets. (F) Distribution of genes below the
threshold p-value from each dataset in 16 common significant pathways.
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Kim et al. BMC Genomics  (2015) 16:279 Page 6 of 15distributed on the 16 overlapping pathways in all three
datasets (Figure 4F; also refer to the significant path-
ways from each dataset in Additional file 3: Table S3).
Comparison of the significant pathways extracted
from one optimal PCA method with those from
weighted PCA (see Methods) disclosed similar results
(Additional file 4: Figure S1). Interestingly, signaling
pathways related to cell proliferation and invasiveness,
such as mitogen-activated protein kinase (MAPK),
ErbB, G protein-coupled receptor (GPCR), and mem-
brane integrity-related pathways, such as those involv-
ing actin cytoskeleton, axon guidance and adhesion,
were significantly associated with recurrence in our
HBV-HCC dataset (Figure 4F and Additional file 3:
Table S3). Moreover, all significant pathways obtained
from each dataset (log-rank p-value < 0.01 in the test
set) were associated with early recurrence within two
years, with area under curve (AUC) > 0.6. For example,
in Kaplan-Meier plots and receiver operating character-
istic (ROC) curves of the axon guidance pathway, one
significant pathway common to all datasets clearly dis-
tinguished patients according to recurrence risk, with
AUC > 0.65 (Additional file 5: Figure S2).
Subgroup classification via semi-supervised clustering of
pathways
To utilize individual pathway information, sample scores
obtained from optimal principal components of the 64
recurrence-associated pathways were hierarchically clus-
tered using unsupervised clustering analysis of gene
expression [7,14], as depicted in Figure 2. Figure 5A
shows the resulting two subgroups of HCC patients with
different outputs of recurrence (log rank p-value < 0.0001
in Figure 5B). Similar to the gene expression-based ap-
proach, the pathway-based assay classified patients with
early recurrence within 2 years after surgery predomin-
antly in the high-risk, relative to the low-risk subgroup.
The robustness of the two subgroups was validated
using leave-one-out cross-validation with six algo-
rithms, including compound covariate, diagonal linear
discriminant analysis, 1-nearest neighbor, 3-nearest
neighbor, nearest centroid, and support vector machine.
The algorithms clearly divided the high- and low-risk
subgroups with cross-validated misclassification error
rate below 0.1 and corresponding p-values < 0.0001,
based on 1,000 random permutations (Figure 5C). ROC
curve computed with compound covariate algorithm
values from subgroup classification using the principal
components matrix showed an AUC value of 0.708 for
early recurrence with sensitivity and specificity of 0.72
and 0.64, respectively (Figure 5D). Similarly, 90 and 32
recurrence-associated pathways obtained from the public
HBV-HCC and HCV-HCC datasets, respectively, clearly
discriminated high-risk and low-risk recurrence subgroups(p-value < 0.0001) (Additional file 6: Figure S3A~C and
Additional file 7: Figure S4A~C). ROC curves addition-
ally showed that these pathways are significantly associ-
ated with early recurrence in both datasets (Additional
file 6: Figure S3D and Additional file 7: Figure S4D).
Our findings indicate that combining the recurrence-
associated pathways increases the statistical significance
of patient classification according to recurrence risk.
Since our approach using optimal principal compo-
nents was dependent on data structure, such as micro-
array platform and experimental conditions, we could
not directly apply coefficients obtained from our micro-
array dataset to the other independent microarray data-
sets. Therefore, only pathway information from our
HBV-HCC dataset was used to validate the effectiveness
of pathway analysis in the public microarray datasets.
Using our 64 recurrence-associated pathways, sample
scores from the first, not optimal, principal component
were measured and clustered in public HBV (Figure 5E)
and public HCV datasets (Figure 5F). As a result, two
subgroups (low- and high-risk) were assigned, depending
on the recurrence outcome. As expected from the sig-
nificant number of common pathways among the three
datasets (Figure 4D), these 64 pathways from our HBV-
HCC dataset were also effective in discriminating pa-
tients of public microarray datasets according to risk
(log rank p-value < 0.001).
Clinical association of recurrence-related pathways
Next, we examined the clinical implications of the
recurrence-associated 64 pathways in our HBV-HCC
dataset (Table 1). Clinicopathological variations (p-value
< 0.05) associated with the high-risk subgroup classified
according to pathway analysis included high levels of
aspartate aminotransferase (≥40 IU/L) and alanine ami-
notransferase (≥40 IU/L), and presence of vascular
invasion and lobular activity. Absence of capsule and
narrow resection margin (<2 cm) were also marginally
associated with the high-risk subgroup (p-value < 0.1).
Univariate analysis showed that the 64 pathways (p-value
< 0.0001), together with clinicopathological parameters,
including tumor stage (p-value = 0.0404), tumor number
(p-value = 0.0125), tumor size (p-value = 0.0072), vascular
invasion (p-value = 0.0059), lobular activity (p-value =
0.0065), Child-Pugh score (p-value = 0.0596), Edmonson
Steiner’s grade (p-value = 0.0764) and capsule formation
(p-value = 0.0560), are significantly or marginally associ-
ated with HCC recurrence in our present cohort. Multi-
variate analysis further led to the definition of these
pathways (p-value < 0.0001) as an independent prognostic
factor for recurrence together with clinical variables,
including tumor number (p-value = 0.0212), tumor size
(p-value = 0.0066) and Edmondson Steiner’s grade (p-
value = 0.0082), in our HBV-positive HCC dataset. In
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Figure 5 Cluster analysis of recurrence-related pathways. (A) Dendrogram of the clustering pattern measured from the matrix of principal components
of 64 recurrence-associated pathways (p-value < 0.01) from HBV-HCC. Samples were classified into two subgroups: low-risk and high-risk. The black bar
indicates patients with early recurrence within 2 years after surgery. Columns represent individual samples, and rows pathways. Red and green colors
reflect high and low levels of optimal principal component scores, respectively, as indicated by scale bars. (B) Kaplan-Meier plots for recurrence rates of
low- and high-risk subgroups. P-values were obtained using the log-rank test. (C) Cross-validation of the low- and high-risk subgroups using six different
algorithms: compound covariate (CC), diagonal linear discriminant (DLD), 1-nearest neighbor (1-NN), 3-nearest neighbor (3-NN), nearest centroid (NC) and
support vector machine (SVM), implemented in BRB ArrayTools. (D) ROC curve computed with the compound covariate validation algorithm for subgroup
classification. (E and F) Dendrogram of the clustering pattern measured from the matrix of principal components of public HBV-HCC (E) or
public HCV-HCC (F) on the 64 pathways associated with recurrence in our HBV-HCC dataset.
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(Figure 6A), the recurrence-associated 64 pathways led to
the extraction of a subgroup showing poor prognosis from
patients with small tumors (<3 cm) in our HBV-HCC
dataset (Figure 6B). Similarly, recurrence-associated path-
ways in the public HBV-HCC dataset facilitated theTable 1 Relationships between recurrence-associated pathwa
Pathways-based subgroups
Variables Low
risk
High
risk
Gender (Male/Female) 52/14 65/11
Age (<50 y/≥50 y) 26/40 27/49
Platelet (<170 × 109/L/≥170 × 109/L) 33/25 28/36
4AST (<40 IU/L/≥40 IU/L) 40/26 31/45
4ALT (<40 IU/L/≥40 IU/L) 41/25 33/43
Bilirubin (<1 mg/dL/≥1 mg/dL) 44/22 42/34
4AFP (<300 ng/mL /≥300 ng/mL) 41/25 52/23
Child-Pugh (A/B,C) 63/3 65/10
UICC (I,II/III,IV) 39/25 50/22
Size (<3 cm/≥3 cm) 14/52 12/64
Number (Single/Multiple) 56/10 64/10
Necrosis (No/Yes) 33/33 25/50
Edmondson’s grade (I,II/III,IV) 45/19 45/27
Vein invasion (Absent/Present) 49/12 39/31
Lobular activity (No/Yes) 39/25 18/56
Capsule (Absent/Present) 47/19 64/11
Margin (<2 cm/≥2 cm) 35/31 51/23
Cirrhosis (Absent/Present) 37/29 41/34
Recurrence-associated pathways - -
Recurrence-associated pathways
Number (Single/Multiple)
Size (<3 cm/≥3 cm)
Edmondson’s grade (I,II/III,IV)
1p-values were calculated using χ2 test.
2CI represents confidence interval.
3p-values were calculated using the Cox Proportional Hazards Model.
4AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, α-fetoprotein
Bold data indicate statistically significant values (p<0.05).identification of a subgroup of early recurrence in patients
with small tumors (<5 cm) (Additional file 8: Figure S5).
In addition, Edmondson Steiner’s grade (Figure 6C) and
tumor number (Figure 6D), significant parameters in
multivariate analysis (Table 1), were effective in the extrac-
tion of a subgroup with early recurrence from patientsys and clinicopathological variables in HBV-HCC
Recurrence analysis
Univariate analysis
P-value1 Hazard ratio
(95% CI)2
Log rank
p-value3
0.406 0.563 (0.320 0.991) 0.0439
0.763 1.056 (0.706 1.577) 0.790
0.204 1.019 (0.675 1.538) 0.928
0.0287 1.096 (0.745 1.613) 0.639
0.0397 1.003 (0.682 1.477) 0.984
0.224 1.050 (0.708 1.556) 0.806
0.469 0.976 (0.644 1.480) 0.912
0.131 1.813 (0.967 3.401) 0.0596
0.389 1.519 (1.015 2.273) 0.0404
0.538 2.178 (1.216 3.901) 0.00726
0.972 1.874 (1.135 3.094) 0.0125
0.0664 1.565 (1.048 2.339) 0.0273
0.435 1.273 (0.974 1.665) 0.0764
0.00501 1.787 (1.175 2.718) 0.00594
2.879 × 10−5 1.770 (1.166 2.685) 0.00652
0.0660 0.617 (0.374 1.017) 0.05603
0.0794 0.836 (0.557 1.256) 0.389
0.997 1.257 (0.853 1.852) 0.245
- 2.843 (1.881 4.295) 2.416 × 10−7
Multivariate analysis
3.220 (2.076 4.994) 1.760 × 10−7
1.839 (1.095 3.089) 0.0212
2.489 (1.288 4.808) 0.00666
1.769 (1.159 2.701) 0.00821
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Figure 6 Stratification of small tumor size patients by recurrence-associated pathways. (A) Kaplan-Meier plot for recurrence rates in two
subgroups of patients based on tumor size (< and >3 cm) in our HBV-HCC dataset. P-values were obtained using the log-rank test. (B-D)
Application of recurrence-associated pathways to patients with small tumors (<3 cm) (B), Edmonson Steiner’s grade (I and II) (C) or single
nodules (D) led to further stratification into two subgroups with different recurrence rates.
Kim et al. BMC Genomics  (2015) 16:279 Page 9 of 15with Edmondson Steiner’s grade I and II or single nodular
status. These findings further validate the clinical utility of
our pathway-based approach when combined with other
clinical variables.Discussion
The identification of common biological features associ-
ated with HCC prognosis based on gene expression pat-
terns that are interchangeable among different patient
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genes among patient cohorts are extremely limited. As ex-
pected, common significant recurrence-associated genes
were rare among the HCC datasets examined in the
present study, with only 4.8% overlapping genes identified
between the two HBV-positive HCC groups. Several fac-
tors may contribute to the observed rarity of common
genes. Heterogeneity of patients in terms of clinicopatho-
logical characteristics as well as differences in microarray
platforms and experimental conditions are among the
main causes of inconsistent microarray results among
datasets. A gene set-based approach (pathway analysis)
was recently shown to partly overcome the heterogeneity
of microarray analysis [10,13,14]. The use of biologically
related gene sets may be a more robust approach to sup-
press clinicopathological heterogeneity [12].
Data from the present study confirmed that the
pathway-based approach is more beneficial than the
gene-based approach in identifying common biological
features in HCC recurrence. For this purpose, we devel-
oped a pathway-based PCA algorithm. Previously, PCA
using a subset of genes was reported to accurately pre-
dict clinical outcomes of patients [14]. Here, we used an
optimal component, rather than the first or second prin-
cipal component. Despite the rarity of common genes
between the two HBV-positive HCC datasets, a large
proportion (71.9%) of the significant pathways over-
lapped. Interestingly, 16 pathways (28.1%) were common
among our HBV-positive HCC group and the two public
HBV and HCV-positive HCC datasets, as shown in
Figure 4D (see also Additional file 3: Table S3).
Our cohort exhibited a biphasic pattern in which the
majority of recurrence occurred within the first two
years, similar to the public HBV-HCC cohort [3]. Con-
sidering that recurrence is critically linked to survival in
HCC, understanding the pathways associated with early
recurrence is crucial for effective clinical management of
the disease. Our pathway-based approach using optimal
principal components was associated with early recur-
rence occurring within two years, with high sensitivity
and specificity in ROC curve analysis. Interestingly, pa-
tients with poor prognosis could be distinguished among
those with small tumors using the present approach.
The finding that recurrence-associated pathways may be
an independent variable for HCC recurrence along with
tumor number, tumor size and Edmondson’s grade sup-
ports the clinical utility of our method.
Although the 16 pathways were common in both
HBV- and HCV-HCC datasets, their clinical advantage
in patient classification was not clear. Since these com-
mon pathways were not optimal, we obtained reduced
performance in classification of patients. In addition to
its clinical value, the overlap of significant pathways be-
tween HBV- and HCV-positive datasets further suggeststhat recurrence of HBV- and HCV-positive HCCs is
commonly affected by dysfunction of common biological
pathways (including hemostasis, platelet activation,
transmembrane transporter, actin cytoskeleton, axon
guidance, immune signaling, MAPK signaling, ErbB sig-
naling, and GPCR signaling). Notably, these pathways
have already been reported in association with develop-
ment or prognosis in diverse types of human cancers,
including HCC. For example, hemostasis and platelet-
related pathways are critical in cancer development
[21,22]. Signaling pathways, such as MAPK and ErbB,
and immune-related pathways are involved in prognosis
and tumorigenesis of HCC [23-26]. G-protein pathways,
including GPCR signaling, are de-regulated in diverse
types of cancers and can thus be effectively used as
prognostic markers [27]. Moreover, enrichment of immune
response pathways (25%, 16 out of 64 recurrence-
associated pathways in Additional file 3: Table S3) supports
a close association of the high-risk subgroup with lobular
activity, a clinical parameter for inflammation (Table 1).
Lobular activity status is related to not only these
recurrence-associated pathways, but also a subset of
recurrence-associated genes, as shown in Additional file 9:
Figure S6. Under the condition where 206 genes were se-
lected as associated with lobular activity (p < 0.001, t-test),
23 (p < 0.01, log-rank test) were related to recurrence
(p < 0.0001, chi-square test). These gene sets exhibited dif-
ferential expression profiles according to differences in
lobular activity. Other diverse pathways, such as lysosome,
endocytosis, and hemostasis, were additionally associated
with recurrence. Although the functional involvement of
these pathways in human cancer has not been fully eluci-
dated, studies have shown that the lysosomal pathway is a
novel target of cell death in cancer [28]. Moreover, lyso-
somal proteins, such as lysosome-associated membrane
protein-1 [29] and lysosomal cysteine proteases [30], are as-
sociated with tumor development and progression. The
clathrin-mediated endocytosis pathway connected with the
cytoskeleton has been shown to regulate functional changes
in HCC [31]. This association of diverse functional path-
ways clearly indicates that recurrence is a complex process
involving changes in various biological functions.
In contrast to the common pathways discussed above,
tight junction, focal adhesion and integrin pathways were
more significantly associated with HBV-positive HCC.
These membrane mobility and intercellular interaction
pathways are involved in HCC invasion, metastasis and
angiogenesis [32-34]. Interestingly, sphingolipid metabolism
was mainly associated with recurrence of HCV-positive
HCC. Accumulating evidence suggests that sphingolipid
regulates cell death in liver diseases, including HCC [35,36].
Previously, we reported functional differences and simi-
larities in pathways implicated in the development of HCV-
and/or HBV-positive HCC [12,37]. By comparing these
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we obtained those commonly involved in both processes in
HBV-positive and HCV-positive HCC. In the HBV-positive
HCC dataset, 26 out of 64 recurrence-associated pathways
(40.6%) were associated with tumorigenesis, while 12
out of 32 recurrence-associated pathways (37.5%) were
involved in tumorigenesis in the public HCV-HCC
dataset (Additional file 10: Figure S7). Involvement of a
relatively large proportion of recurrence pathways in
tumorigenesis signifies that the biological processes as-
sociated with hepatocarcinogenesis also determine the
prognostic process. Moreover, a number of pathways,
including axon guidance, lysosome, actin cytoskeleton,
and GPCR signaling, were shared between the HBV-HCC
and HCV-HCC datasets (Additional file 11: Figure S8),
highlighting the possibility that a common process affects
tumor development to prognosis, irrespective of the viral
origin of HCC.
We further validated our pathway-based classification of
HCC patients with those published employing prognostic
genes for HCC. Survival-associated genes identified by Lee
et al. [2] and Hoshida et al. [8], as well as recurrence-
associated genes from the public HBV- and HCV-HCC
datasets, led to grouping of patients into subclasses signifi-
cantly associated with those obtained with the pathway-
based approach using 64 pathways (Additional file 12:
Figure S9). Among the patients classified as high-risk
based on our 64 recurrence-associated pathways, a signifi-
cant number (p < 0.05) belonged to the high-risk sub-
classes identified based on each of the four different
survival or recurrence gene sets. This comparative result
further confirmed that our pathway-based classification of
HCC prognosis is compatible with prior classification sys-
tems using survival- and recurrence-associated genes.
Conclusions
Our pathway-based approach using optimal PCA was
more advantageous than the gene-based approach in
several aspects, and revealed common prognostic path-
ways between HCC datasets of different patient cohorts,
despite the rarity of common recurrence-associated genes.
Identification of these shared pathways allowed the evalu-
ation of functional similarities and differences between
HBV- and HCV-positive HCCs. Further studies are essen-
tial to validate the specific functions of these pathways in
addition with HCC recurrence.
Methods
HCC dataset
The HBV-positive HCC dataset (HBV-HCC) was com-
posed of 142 HCC tissues from patients subjected to
surgical resection at Korea Cancer Center Hospital and
Seoul National University Hospital at Korea from March
1992 to July 2004. The tissue specimens were immediatelycollected after resection, and stored in liquid nitrogen
until RNA extraction for microarray experiment. The
present retrospective study was approved by the Insti-
tutional Review Boards of Seoul National University
Hospital and Korea Cancer Center Hospital. Written
informed consent was obtained from the patients of
Seoul National University Hospital or waived by the
Institutional Review Board of Korea Cancer Center
Hospital. Prior to analysis, patient information was
anonymized and de-identified. Clinicopathologic data
were obtained retrospectively, including platelet, biliru-
bin, alanine transaminase, aspartate aminotransferase,
α-fetoprotein, Child-Pugh score, tumor size, tumor
number, tumor grade, vein invasion, lobular activity,
capsule formation, resection margin, and cirrhosis.
Microarray experiment
Total RNA from HCC tissues was extracted using the
Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA), in ac-
cordance with the manufacturer’s instructions. The quan-
tity and quality of purified RNA were measured using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA), and only samples with RNA integrity number
(RIN) greater than 7.0 were included in the microarray
analysis [38,39]. Total RNA isolated from frozen tissues
was reverse-transcribed to cDNA, labeled with fluorescent
dye (Cy5 for HCC and Cy3 for reference normal liver con-
trol) and hybridized to microarray using a 3-DNA array
detection system (Genisphere, Hatfield, USA). Equal mix-
tures of total RNA from five metastatic liver cancers with
no evidence of cirrhosis, which originated from other or-
gans, were used as a reference control. Approximately
25,000 cDNAs (representing ~11,000 genes) were printed
onto glass microscope slides. Hybridized microarrays were
scanned using a ScanArray (Perkin-Elmer, Boston, USA).
Primary signal intensities were obtained using ImaGene
6.0 software (Bio-discovery, Marina del Rey, USA). The
distribution of signal intensities of fluorescent probes was
assessed using MA and QQ plots to exclude inadequate
samples for analysis (Additional file 13: Figure S10). Only
spots for which signal intensities were greater than 1.4-
fold, compared to those of the local background, were
normalized using the lowess and quantile method to elim-
inate intensity bias [40,41]. After averaging the ratios of
multiple probes per single gene, 9,357 genes were included
in the present study.
Public microarray datasets
Two publicly available microarray datasets were uti-
lized for comparison. The first dataset (Public HBV-
HCC), archived in the Gene Expression Omnibus with
the accession number GSE14520, is composed of 236
HBV-positive HCC specimens [3], and provides infor-
mation on gene expression based on a single-channel
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normalized the probe intensities of each array using the
quantile method [41]. After averaging multiple probes
per single gene, 13,345 genes were ultimately subjected
to analysis. The second set (Public HCV-HCC) is com-
posed of 43 HCV-positive specimens (GSE17856) [4].
Gene expression of this dataset is based on oligo-
microarrays (Agilent-014850 Whole Human Genome
Microarray) in which Cy5 and Cy3 fluorescent dyes
were used to label RNAs from tissue samples and refer-
ence control, respectively. We normalized logarithm
values of the probe intensity ratio (Cy5/Cy3) using the
quantile method [41]. Multiple probes per single gene
were averaged to produce a final set of 14,411 genes.
Clinical comparisons of the three datasets are pre-
sented in Additional file 2: Table S1.Identification of recurrence-related genes
Genes associated with recurrence were selected using
BRB ArrayTools (version 3.6, http://linus.nci.nih.gov/
BRB-ArrayTools.html) in which expression values are
correlated with recurrence time using the Cox Pro-
portional Hazards Model. The log-rank p-values for
individual genes were tested one at a time for the
hypothesis that recurrence time is independent of the
expression level for that gene. The p-values were ap-
plied to construct gene lists using multivariate permuta-
tion tests for controlling the number or proportion of
false discoveries with 10,000 iterations.Pathway-based supervised Principal Component Analysis
Initially, samples were randomly split into two groups:
training (60%) and test sets (40%). PCA analysis was
performed in the training set with genes belonging to
each pathway. First, in each pathway, we selected a
single optimal principal component most significantly
associated with recurrence in Cox proportional haz-
ards regression. The optimal principal component was
subsequently applied to the test set to obtain sample
scores. In weighted PCA, the principal components
responsible for over 80% variance in the training set
were selected and linearly added to generate the sam-
ple score using regression coefficients of individual
components as weight. This procedure was repeated
1,000 times to facilitate maximum extraction of infor-
mation from all samples. Next, the median value of
statistics over the entire permutation process was com-
puted on each pathway. The statistical significance of
the test validation outcomes was computed by compar-
ing with results from randomly selected pathways with
1,000 iteration times. All procedures were performed
in R (v2.14.0). The R source code for the program is
available on request.Determination of the threshold p-value
Genes were ranked and ordered according to log-rank
p-values on Cox proportional hazards regression. We ap-
plied permutation-based (n = 1,000) pathway analysis, as
described above, starting from genes with the lowest uni-
variate p-value and gradually increasing the number of
genes, and measured the average number of pathways
below the log-rank p-value of 0.01 in the test set. The
threshold was taken as the p-value with the maximum
number of significant pathways in the test set.Pathway information
Manually curated pathways were obtained from the Mo-
lecular Signatures Database (MSigDB, http://www.broadin-
stitute.org/gsea) [10] including 186 pathways from Kyoto
Encyclopedia of Genes and Genomes [42], 217 from Bio-
Carta (http://www.biocarta.com/genes/allPathways.asp) and
430 from Reactome [43]. Among a total of 833 pathways,
only those containing at least 10% of microarray genes in
each pathway were used in the experiment.Pathway cluster
For pathway-based clustering of samples, we constructed
a matrix composed of optimal principal component scores
for each sample and pathway. The matrix was hierarchic-
ally clustered based on similarities of the principal compo-
nents to classify the samples [44]. For robustness of the
resultant subclasses, cross-validation using the leave-one-
out method was implemented in BRB ArrayTools using
six different validation algorithms, including the com-
pound covariate, diagonal linear discriminant, 1-nearest
neighbor, 3-nearest neighbor, nearest centroid and support
vector machine. The statistical significance of misclassifi-
cation error was determined using random permutation
of samples (N = 1,000). The differences in recurrence rates
between subclasses were estimated using the Kaplan-
Meier method with log-rank test. ROC curve for recur-
rence assessment was measured from the compound co-
variate algorithm for subgroup classification using the
survival ROC R package [45].Other pathway-based analyses
For a pathway composed of N genes, LS statistics is
used to measure the average value of negative natural
logarithms of single gene p-values. KS statistics allow
calculation of the maximum difference between i/N
and ith smallest p-value. The significance of LS and KS
was evaluated by computing the distribution of these
statistics in a random sampling of 1,000 times [46].
ROC-AUC for each pathway was evaluated from the
values of principal components with the survival ROC
R package.
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Our HBV-HCC microarray dataset is available online at
the Gene Expression Omnibus (http://www.ncbi.nlm.-
nih.gov/geo) under the ID number GSE55039.Additional files
Additional file 1: Table S1. Top 20 recurrence-associated genes in our
HBV-HCC dataset.
Additional file 2: Table S2. Clinicopathological information on three
HCC datasets.
Additional file 3: Table S3. Pathways associated with recurrence in
each HCC dataset.
Additional file 4: Figure S1. Comparison of one-optimal PCA and weighted
PCA methods. Log-rank p-values of 882 pathways calculated with the two
methods were compared. One-optimal PCA used one principal component
optimally associated with recurrence while weighted PCA used multiple
principal component sex plaining over 80% variance in each dataset.
Additional file 5: Figure S2. Association of the axon guidance pathway
with recurrence of HCC. Kaplan-Meier plot sand receiver operating
characteristic (ROC) curve with the axon guidance pathway in HBV-HCC,
public HBV-HCC and public HCV-HCC. For the Kaplan-Meier plot, samples
were classified in to two subgroups based on the median value of principal
components of the axon guidance pathway.
Additional file 6: Figure S3. Cluster analysis of recurrence-related
pathways. (A) Dendrogram of clustering pattern measured from the
matrix of principal components of 90 recurrence-associated pathways
(p-value < 0.01) from public HBV-HCC. Samples were classified into two
subgroups: low-risk and high-risk based on recurrence out come.
Columns represent individual samples, and rows pathways. Red and
green colors reflect high and low levels of optimal principal component
scores, respectively, as indicated by scale bars. (B) Kaplan-Meier plots for
recurrence rates of the low-and high-risk subgroups. (C) Cross-validation of
the low-and high-risk subgroups using six different algorithms: compound
covariate (CC), diagonal line ardiscriminant (DLD), 1-nearest neighbor (1-NN),
3-nearest neighbor (3-NN), nearest centroid (NC) and support vector
machine (SVM). (D) ROC curve computed with CC validation algorithm
for subgroup classification.
Additional file 7: Figure S4. Cluster analysis of recurrence-related
pathways. (A) Dendrogram of clustering pattern measured from the
matrix of principal components of 32 recurrence-associated pathways
(p-value < 0.01) from public HCV-HCC. Samples were classified into
two subgroups: low-risk and high-risk based on recurrence out come.
Columns represent individual samples, and rows pathways. Red and green
colors reflect high and low levels of optimal principal component scores,
respectively, as indicated by scale bars. (B) Kaplan-Meier plots for recurrence
rates of the low-and high-risk subgroups. (C) Cross-validation of the low-and
high-risk subgroups using six different algorithms: compound covariate (CC),
diagonal line ardiscriminant (DLD), 1-nearest neighbor (1-NN), 3-nearest
neighbor (3-NN), nearest centroid (NC) and support vectormachine (SVM).
(D) ROC curve computed with CC validation algorithm for subgroup
classification.
Additional file 8: Figure S5. Stratification of small tumor-size patients
by recurrence-associated pathways. (A) Kaplan-Meier plot for recurrence
rates in two subgroups of patients based on tumorsize (<and > 5 cm)
in public HBV-HCC dataset. (B) Application of subgroup information
determined from recurrence-associated pathways to small tumor-size
patients (<5 cm) led to further stratification into two subgroups with
different recurrence rates.
Additional file 9: Figure S6. Genes associated with lobular activity. A total
of 206 genes were selected as differentially expressed (p < 0.001 with t-test)
according to status of lobular activity. Among these genes, 23 were
significantly associated with recurrence using the log-rank test (p < 0.01).
Additional file 10: Figure S7. Comparison of recurrence-associated and
tumorigenic pathways. Recurrence-associated path ways identified in thepresent study were compared with those associated with tumorigenesis
in HCC obtained from our prior analysis of the same public HBV and
HCC datasets [12]. In total, (A) 64 recurrence-associated pathways from
our HBV-HCC dataset (log-rank p-value < 0.01 in the testset) were compared
with 84 tumorigenic pathways from another HBV-positive HCC dataset (error
rate < 0.1), and (B) 32 recurrence-associated pathways from public HCV-HCC
(log-rank p-value < 0.01 in the testset) compared with 138 tumorigenic
pathways from the same dataset (error rate < 0.1).
Additional file 11: Figure S8. Distribution of recurrence-associated and
tumorigenic pathways.
Additional file 12: Figure S9. Comparison of patient classification. With
previously reported prognosis-associated genes (Lee et al. [2], Hoshida
et al. [8], public HBV-HCC [3] and public HCV-HCC u datasets), patient
subclasses were determined using hierarchical clustering, and compared
with subgroups obtained from our pathway-based method. Blue and red
colors represent low-and high-risk subgroups, respectively, while white
(public HBV-HCC) signifies the intermediate subgroup. Statistical significance
was measured using Fisher’s exact test in comparison with pathway-based
low-and high-risk subclasses.
Additional file 13: Figure S10. MA and QQ plots for assessing sample
quality before normalization. The distribution of signal intensities of
fluorescent probes was examined using MA and QQ plots. Older and
newer samples indicate those collected before 1995 and after 2000,
respectively. For QQ plot, we used the newest sample, S174, as a
common reference.
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